No, don't think it is dead. If it was up to me, post marketing data from EU would be fine. The FDA - dunno, they might want another trial comparing the 2 doses with longer safety data.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.